Recruiting · registry status

Following Parkinson’s and a related condition in Shanghai

Researchers collect detailed clinical information on people with Parkinson’s or multiple system atrophy to support understanding and future research.

Learning by observing or collecting information · Study reference: NCT07353463

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date): 2025-04-01
Main measurements finished (planned): 2026-12-31
Study finished (planned): 2026-12-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age range not listed · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

* Inclusion Criteria for Clinical PD Group: 1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\_. 2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments. 3. Provision of written informed consent * Inclusion Criteria for Clinical MSA Group: 1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022). 2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments. 3. Provision of written informed consent. * Exclusion Criteria for All Participants: 1. Patients with an unclear or uncertain diagnosis. 2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery. 3. Evidence of intracranial organic lesions on CT/MRI. 4. Severe anxiety, depression, or schizophrenia. 5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system. 6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments. 7. Anticipated poor compliance.

Full study name & original research details

Official study title

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

Original description

The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development. The main questions it aims to answer are: * Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA? * Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis. Participants will: * Provide informed consent and complete baseline demographic and medical history collection. * Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments. * Provide biological samples (blood, saliva, optional CSF). * Receive brain imaging (MRI, optional PET/SPECT) and electrophysiological recordings (EEG, fNIRS). * Participate in longitudinal follow-up visits every 6 months for repeat assessments. This study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases

Conditions reported: Parkinson's Disease (PD); Multiple System Atrophy

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

ClinicalTrials.gov · NCT07353463 ↗ — RECRUITING; checked 2026-10-13

Study type: Observational
Interventions: Not reported
Phases: Not reported
Sponsor: Ruijin Hospital
Start date reported by registry: 2025-04-01 (actual)

Registry updated: 2026-03-05 · Status last verified by the registry submitter: 2025-04

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Jun Liu, Professor · +86-021-64370045 · lj11128@rjh.com.cn

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

Recruiting

Jun Liu, Professor · +86-021-64370045 · lj11128@rjh.com.cn

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.